The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Open accessAbstract
In December 2019, a new and highly pathogenic coronavirus emerged—coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), quickly spread throughout the world. In response to this global pandemic, a few vaccines were allowed for emergency use, beginning in November 2020, of which the mRNA-based vaccines by Moderna (Moderna, Cambridge, MA, USA) and BioNTech (BioTech, Mainz, Germany)/Pfizer (Pfizer, New York, NY, USA) have been identified as the most effective ones. The mRNA platform allowed rapid development of vaccines, but their global use is limited by ultracold storage requirements. Most resource-poor countries do not have cold chain storage to execute mass vaccination. Therefore, determining strategies to increase stability of mRNA-based vaccines in relatively higher temperatures can be a game changer to address the current global pandemic and upcoming new waves. In this review, we summarized the current research strategies to enhance stability of the RNA vaccine delivery system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degradation of mRNA in the presence of water, attributed to oxidation and hydrolysis43, required mRNA vaccines to be stored and transported at subzero temperatures.”
From An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial (2024) · cites this paper as [43]
Experimental — accuracy not yet measuredIn the citing paper
“For instance, the mRNA-1273 vaccine from Moderna maintains its effectiveness for six months at −20 °C, whereas the effectiveness of the BNT162b2 vaccine from BioNTech is maintained for six months when stored at −60 to −80 °C. Conversely, the CVnCoV vaccine from CureVac can be stored at −60 °C for three months.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [469]
In the citing paper
“Therefore, existing COVID-19 mRNA vaccines undoubtedly require storage under ultra-low temperatures.469”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [469]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 4×
“Both Moderna and Pfizer modified the mRNA encoding viral spike protein by replacing natural residues with two consecutive prolines at amino acid positions K986 and V987 for their COVID-19 vaccines [5,6,8].”
BackgroundInfluentialEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
The Many Pathways of RNA Degradation
Houseley, J. M., & Tollervey, D. W. (2009) · Cell · doi:10.1016/j.cell.2009.01.019 · Cited by 1,220
Lyophilization and development of solid protein pharmaceuticals
Wang, W. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00423-3 · Cited by 1,178
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927
A thermostable mRNA vaccine against COVID-19
Zhang, N.-N., Li, X.-F., Deng, Y.-Q., Zhao, H., Huang, Y.-J., Yang, G., Huang, W.-J., Gao, P., Zhou, C., Zhang, R.-R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.024 · Cited by 671
Gene delivery by lipoplexes and polyplexes
de Ilarduya, C. T., Sun, Y., & Düzgüneş, N. (2010) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2010.03.019 · Cited by 626
Opportunities and Challenges in the Delivery of mRNA-Based Vaccines
Wadhwa, A., Aljabbari, A., Lokras, A., Foged, C., & Thakur, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020102 · Cited by 584
Research works printed but not linked: 1
- Roth, N., Schoen, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S.O., Petsch, B., and Rauch, S. (2021). CV2CoV, an enhanced mRNA-based SARS-CoV-2 vaccine candidate, supports higher protein expression and improved immunogenicity in rats. bioRxiv.
Cited by
Sorted by citations
Items 201–300 of 371
In Situ Stability Test for mRNA Vaccines Based on Deep-UV Resonance Raman Spectroscopy
Almehmadi, L. M., Reverdatto, S., Ermolenkov, V. V., Shekhtman, A. G., & Lednev, I. K. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c01761 · Cited by 6
Nucleic Acid Vaccines Encoding Proteins and Virus-like Particles for HIV Prevention
Tarrés-Freixas, F., Clotet, B., Carrillo, J., & Blanco, J. (2024) · Vaccines · doi:10.3390/vaccines12030298 · Cited by 6
Pawar, S., Pingale, P., Garkal, A., Osmani, R. A. M., Gajbhiye, K. R., Kulkarni, M., Pardeshi, K., Mehta, T. A., & Rajput, A. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.131139 · Cited by 6
mRNA Technology in Modern Medicine: Review and Future Prospects
Silva, H. M. (2025) · Clinical and Molecular Epidemiology · doi:10.53964/cme.2025001 · Cited by 4
Recent Developments of RNA Vaccines and Therapeutics: Reagents, Formulations, and Characterization
Tomeh, M. A., Smith, R. K., & Watkinson, A. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00670 · Cited by 8
Yang, M. J., Kim, J., Lee, Y., Lee, W., & Park, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063099 · Cited by 6
Hayashi, H., Sun, J., Yanagida, Y., Otera, T., Tai, J. A., Nishikawa, T., Yamashita, K., Sakaguchi, N., Yoshida, S., Baba, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-40172-y · Cited by 6
mRNA-Based Nanomedicine: A New Strategy for Treating Infectious Diseases and Beyond
Prakash, S. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00849-1 · Cited by 6
Makhijani, S., Elossaily, G. M., Rojekar, S. V., & Ingle, R. G. (2024) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2024.2361656 · Cited by 7
Analyzing economic effect on mRNA vaccine inventory management with redistribution policy
Kim, H., Cha, H., & Cheong, T. (2024) · Scientific Reports · doi:10.1038/s41598-024-71322-5 · Cited by 6
Recent Advances in mRNA Vaccine DevelopmentPreprint
Aga, A. M., Kelel, M., & Gemeda, M. T. (2023) · Preprints.org · doi:10.20944/preprints202308.0245.v1 · Cited by 5
Realizing temperature-gated photochromic NaYTiO4:Bi3+ for a time–temperature indicator
Bao, Y., Hu, W., Zhou, Y., Qiu, Z., Zhang, J., Zhang, J., Du, J., & Lian, S. (2025) · Science China Materials · doi:10.1007/s40843-025-3279-0 · Cited by 5
Preliminary evaluation of a novel serotype O foot-and-mouth disease mRNA vaccine
Zhao, J., Xiao, P., Xin, A., Zhu, H., Wang, H., Xiao, J., & Gao, H. X. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1503191 · Cited by 5
Tian, T., Zhu, Y., Shang, K., Shi, H., Xu, R., Li, M., Pu, F., Kuang, J., Ding, J., & Zhang, F. (2025) · Vaccines · doi:10.3390/vaccines13060567 · Cited by 5
Mechanomedicine Platforms: Engineering Hydrogel Mechanics for Next‐Generation Vaccines
Yang, M., Tian, J., Qu, K., Zhao, W., Xu, F., & Guo, H. (2025) · Advanced Materials · doi:10.1002/adma.202513783 · Cited by 5
Nkinda, L., Barabona, G., Ngare, I., Nkuwi, E. J., Kamori, D., Msafiri, F., Kunambi, P. P., Osati, E. F. O., Kidenya, B. R., Chuwa, H., et al. (2024) · Journal of Medical Virology · doi:10.1002/jmv.29822 · Cited by 5
Recent Advances in Vaccine Adjuvants: From Lab to Clinic
Vardikar, A., Prajapati, M. K., Gholap, A. D., Rojekar, S. V., Keshari, R., Jain, H., & Rajput, A. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126180 · Cited by 5
Tennant, R., Tetui, M., Grindrod, K., & Burns, C. M. (2022) · IEEE Journal of Translational Engineering in Health and Medicine · doi:10.1109/jtehm.2022.3224740 · Cited by 5
Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis
Jin, T., Wang, H., Liu, Y., & Wang, H. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02413-5 · Cited by 5
Orthoflavivirus zikaense (Zika) vaccines: What are we waiting for?
Cagigi, A., Tinnirello, R., Iannolo, G., & Douradinha, B. G. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107367 · Cited by 5
Biopharmaceuticals for prevention of COVID-19
Farjami, A., Montazersaheb, S., Soofiyani, S. R., Akbarzadehlaleh, P., & Salatin, S. (2022) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.348158 · Cited by 5
Tennant, R., Tetui, M., Grindrod, K., & Burns, C. M. (2022) · JMIR Human Factors · doi:10.2196/39670 · Cited by 5
Yoshizue, T., Brindha, S., Wongnak, R., Takemae, H., Oba, M., Mizutani, T., & Kuroda, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310583 · Cited by 6
A extrafiscalidade e os controles de proporcionalidade e de igualdade
Papadopol, M. D. (2009) · Americanae (AECID Library) · Cited by 5
Tupally, K. R., Seal, P., Pandey, P. M., Lohman, R., Smith, S. C., Ouyang, D., & Parekh, H. S. (2024) · Wiley eBooks · doi:10.1002/9781119987260.ch10 · Cited by 6
Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery
Lam, J. H., Sinsinbar, G., Loo, S. Y., Chia, T. W., Lee, Y. J., Fong, J. Y., Chia, Y. E., Penna, R. R., Liu, S., Pascolo, S., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.4c01820 · Cited by 5
Adjmi, M., Tse, I., & Zangi, L. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000118 · Cited by 4
Development of a Cellular Membrane Nanovesicle-Based Vaccine Against Porcine Epidemic Diarrhea Virus
Wang, X., Zhang, W., Hu, H., Gao, W., Ma, X., Wu, Y., Qiao, Y., Wang, Y., Zhang, D., Dong, C., et al. (2026) · Cells · doi:10.3390/cells15020208 · Cited by 4
Engineered strategies for enhancing mRNA vaccine stability in delivery and storage
Cerav, E. N., Yao, Z., & Sun, B. (2026) · Nanoscale · doi:10.1039/d5nr05189d · Cited by 5
In vivo CAR-T therapy: from molecular design to precision delivery
Li, H., Wen, W., Zhao, X., & Liang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04232-5 · Cited by 4
Nam, J., Ahn, J., Shin, J., Lee, N., Lee, Y. K., Cho, S. M., Kim, P., Kang, G., Ha, S., & Jung, H. (2026) · Advanced Science · doi:10.1002/advs.202522846 · Cited by 4
Archer, M. C., McCollum, J., Press, C., Dutill, T. S., Liang, H., Fedor, D. M., Kapilow-Cohen, L., Gerhardt, A., Phan, T., Trappler, E. H., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17325 · Cited by 4
Foley, L., Ziaee, A., Walker, G., & O’Reilly, E. J. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081020 · Cited by 4
Askarizadeh, A., Vahdat‐Lasemi, F., Karav, S., Kesharwani, P., & Sahebkar, A. (2024) · European Polymer Journal · doi:10.1016/j.eurpolymj.2024.113624 · Cited by 4
Structural Color Liquids with Sol‐Gel Irreversibility for Visualized Freeze‐Thaw Monitoring
Zhao, Q., Huang, C., & Du, X. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202500381 · Cited by 4
Farinha, S., Mota, R., Lopes, C., Vélez, R., Freire, M. G., Aguiar‐Ricardo, A., Rodrigues, M. Â., Marques, L., Cristóvão, J. S., & Lino, P. R. (2025) · AAPS PharmSciTech · doi:10.1208/s12249-025-03133-4 · Cited by 4
Capillary-Mediated Vitrification: Preservation of mRNA at Elevated Temperatures
Renu, S., Shank-Retzlaff, M. L., Sharpe, J., Bronsart, L. L., & Mohanty, P. (2022) · The AAPS Journal · doi:10.1208/s12248-022-00723-z · Cited by 4
Biswal, M. R., Roy, S. K., & Singh, J. K. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.04.616619 · Cited by 4
Trends in uptake and impact of thermostable vaccines in Africa
Kitui, S. K., Juma, E., Ndalama, M. T., Chilot, D., Debela, D. T., Woldemedhin, B., Muzazu, S. G. Y., Heraro, K. D., Mungania, J., & Manyazewal, T. (2025) · Therapeutic Advances in Vaccines and Immunotherapy · doi:10.1177/25151355251341662 · Cited by 3
mRNA Vaccine Development in the Fight Against Zoonotic Viral Diseases
Tan, B. E. K., Tham, S. K., & Poh, C. L. (2025) · Viruses · doi:10.3390/v17070960 · Cited by 4
A modular polymer platform for efficient mRNA delivery in cancer immunotherapy
Lin, G., Huang, J., Li, X., Liu, Y., Juenke, T., Finstad, A., & Zhang, M. (2025) · Nanoscale Horizons · doi:10.1039/d5nh00299k · Cited by 3
Francis, J. A., Wright, L., Oerlemans, S. K., van Wegen, R., & Falconer, R. J. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.126196 · Cited by 3
Hong, X., Li, X., Han, X., Lou, J., Li, Y., Lin, J., Cheng, Y., Xing, H., Zhang, H., Wang, X., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.006 · Cited by 3
Replacing Helper Lipids With Cationic Lipids Enhances mRNA Lipid Nanoparticles Stability in Solution
Chen, R., Xu, L., Zhang, N., Yu, H., Wang, X., Zhai, J., Whelan, F., Elliott, P., & Zhao, C. (2025) · Advanced Science · doi:10.1002/advs.202511637 · Cited by 4
Grassi, C. M., Feng, J., Wahid, R., Kandinov, B., Goel, S., Wang, D., Sellers, K., Dixit, A., Kogawara, O., Das, R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127960 · Cited by 3
Shang, Q., Jiang, C., Wang, X., Guo, M., Liu, J., Jin, Z., Yuan, Y., & Wang, F. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.09.014 · Cited by 3
Ko, E., Hu, J., Jeong, Y., Oh, C., Abdus, S. M., Lee, B.-J., & Park, C. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00795-x · Cited by 5
Chemical engineering strategies to enhance mRNA–LNP stability for therapeutic applications
Zhang, Z., Ong, Y., Yang, B., Fan, B., Yang, Y. Y., & Ni, Q. (2026) · Biomaterials Science · doi:10.1039/d5bm01635e · Cited by 5
Hong, Y., Zi, G., & Peng, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052239 · Cited by 3
Analysis of systemic and behavioral barriers to COVID-19 vaccination in rollout phase
Mishra, V. (2022) · International Journal of Healthcare Management · doi:10.1080/20479700.2022.2157934 · Cited by 3
Formulation Development of a COVID-19 Recombinant Spike Protein-Based Vaccine
Xiao, E., Mirabel, C., Clénet, D., Zhu, S., James, A., Ettorre, L., Williams, T., Szeto, J., Rahman, N., & Ausar, S. F. (2024) · Vaccines · doi:10.3390/vaccines12080830 · Cited by 3
Orthoflavivirus Vaccine Platforms: Current Strategies and Challenges
Unali, G., & Douam, F. (2025) · Vaccines · doi:10.3390/vaccines13101015 · Cited by 3
Soon, H. I., Abdullah, A. A., Nishizaki, H., Mashor, . Y., Kamarudin, L. M., Mohamed‐Hussein, Z., Mohamed, Z., & Ang, W. C. (2024) · International Journal of ADVANCED AND APPLIED SCIENCES · doi:10.21833/ijaas.2024.06.023 · Cited by 3
Immunogenic Comparison of Nucleic Acid-Based Vaccines Administered by Pyro-Drive Jet Injector
Tai, J. A., Nishikawa, T., Hayashi, H., Kuan, Y.-D., Yamashita, K., & Hironori Nakagami, A. (2024) · Vaccines · doi:10.3390/vaccines12070757 · Cited by 3
Marc, G. P., Coria, L. M., Ceballos, A., Rodriguez, J. M., Lombardo, M., Bruno, L. A., Córdoba, F. P., Cassero, C. G. F., Salvatori, M., Medrano, M. R., et al. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127045 · Cited by 3
Park, S., Kim, S., Gu, E.-Y., Park, H.-J., Im, W., Min, S. E., Choi, B.-H., Kim, N., Jang, M. S., Kim, Y. B., et al. (2025) · Journal of Immunotoxicology · doi:10.1080/1547691x.2025.2504401 · Cited by 3
A novel platform for engineered AAV-based vaccines
Babutzka, S., Gehrke, M., Παπαδοπούλου, Α., Diedrichs‐Möhring, M., Giannaki, M., Hennis, L., Föhr, B., Kooyman, C., Osterman, A., Yannaki, E., et al. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101418 · Cited by 2
A spray dried replicon vaccine platform for pandemic response
McClary, W. D., Chen, J. Z., Wang, H., Lo, E., Bakken, J., McCollum, J., Press, C., Melief, E. H., Brandt, D. S., Martin, A. R., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125777 · Cited by 4
Potential of MRNA vaccines for mpox prevention: current evidence and future directions
Abdul‐Rahman, T., Ogungbemi, E. F., Ajetunmobi, O. A., Thaalibi, H. I., Ikele, C. G., Gautam, G., Olanrewaju, O. F., Roy, P., Adebayo, A. A., Mojeed, M. A., et al. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003558 · Cited by 3
Low‐cost, handheld, multi‐pulse electroporators for simplified nucleic acid delivery in skin
Rohilla, P., Azizoğlu, E., Park, S., Lele, A., Prausnitz, M. R., & Bhamla, M. S. (2025) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70070 · Cited by 2
Parish, M. A., Badhwar, S., Tan, H.-L., Causbhoy, I., Kretz, A. M., Sheffield, J. S., Klein, S. L., & Morgan, R. (2025) · npj Women s Health · doi:10.1038/s44294-025-00115-6 · Cited by 3
Nawrin, K., Islam, M. S., Sekine, Y., & Hayami, S. (2025) · Journal of Materials Chemistry B · doi:10.1039/d5tb02528a · Cited by 2
Mujawar, N. K., & Mulla, J. A. S. (2025) · Research Journal of Pharmacy and Technology · doi:10.52711/0974-360x.2025.00886 · Cited by 2
Paila, Y. D., Pajón, R., Banbury, B. L., Fields, P., Maglinao, M., Rosa, S. C. D., Morris, D. E., McElrath, M. J., Siangphoe, U., Cohen, K. W., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01402-2 · Cited by 2
Skelly, E., Majithia, K. J., Rebolledo, L. P., Rizek, C., Costa, S. F., Dunnavant, A. R., Vasquez, C., Lushnikov, A. J., Krasnoslobodtsev, A. V., Kim, T., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c25898 · Cited by 4
Shi, P., Liu, H., Refaat, A., Nguyen, T., Nguyen, A., Miao, K., Song, Y., Trépout, S., Tabor, R. F., de Campo, L., et al. (2026) · Small · doi:10.1002/smll.202511946 · Cited by 2
Ona, N. A., Zhang, D., Lindesmith, L. C., Park, W., Meshanni, J. A., Berkihiser, S., Vasserman, J. A., Toshtzar, S., Moore, N. C., Williams, B., et al. (2026) · Science Advances · doi:10.1126/sciadv.adv1554 · Cited by 2
Emerging Non-Conventional Approaches in mRNA-LNP Formulation for Therapeutic Applications
Zhang, Y., Linaje-Ferrel, G., Angel, J. M. R., Banik, O., Banoth, E., Kamen, A., Yandrapalli, N., & Perumal, A. S. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18050527 · Cited by 2
A hydrogel-entrapped live virus immunization
Gong, N., Hamilton, A. G., & Mitchell, M. J. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01008-2 · Cited by 2
Recent Advances in mRNA Vaccine Development
Aga, A. M., Kelel, M., & Gemeda, M. T. (2023) · Open Access Journal of Microbiology & Biotechnology · doi:10.23880/oajmb-16000275 · Cited by 7
An antibody-free evaluation of an mRNA COVID-19 vaccine
Branham, P. J., Cooper, H. C., Williamson, Y. M., Najjar, F. N., Sutton, W. J. H., Pierce, C. L., Barr, J. R., & Williams, T. L. (2023) · Biologicals · doi:10.1016/j.biologicals.2023.101738 · Cited by 2
Tumor Microenvironment-Responsive Nanoplatforms for Triggering Drug Delivery
Melia, F., Udomjarumanee, P., Rogoyski, R., & Pranjol, M. Z. I. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_412-1 · Cited by 2
Time-traceable micro-taggants for anti-counterfeiting and secure distribution of food and medicines
Park, C., Jeong, Y., Yeom, H., Song, S. W., Park, W., & Lee, D. (2024) · Biomicrofluidics · doi:10.1063/5.0200915 · Cited by 2
Offersgaard, A., Hernandez, C. R. D., Zhou, Y., Duan, Z., Gammeltoft, K. A., Hartmann, K. T., Fahnøe, U., Marichal‐Gallardo, P., Alzua, G. P., Underwood, A. P., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-67570-0 · Cited by 2
Wazed, S. (2024) · The Indian Journal of Medical Research · doi:10.25259/ijmr_1677_2024 · Cited by 2
The Possible Mechanistic Basis of Individual Susceptibility to Spike Protein Injury
Halma, M. T. J., Vottero, P., Thorp, J. A., Peers, T., Tuszyński, J. A., & Marik, P. E. (2025) · Advances in Virology · doi:10.1155/av/7990876 · Cited by 2
Advancements in delivering RNA therapies using physical transdermal drug delivery methods
Nimrawi, S., Al‐Nemrawi, N. K., & Kwon, Y. M. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107587 · Cited by 2
Fischer, L. J., Rains, R. C., Brett-Major, S. M., Senga, M., Holden, D., & Brett‐Major, D. M. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2104500 · Cited by 2
Han, Z., Zuo, T., Ma, C., Li, Y., & Cheng, H. (2023) · Scientia Sinica Chimica · doi:10.1360/ssc-2022-0257 · Cited by 2
mRNA Vaccines for Malaria and Other Parasitic Pathogens
Versteeg, L., & Pollet, J. B. K. (2024) · doi:10.1002/9783527838394.ch11 · Cited by 2
Protective efficacy of pDNA vaccine Candidates against lethal SARS-CoV-2 in Syrian Golden HamstersPreprint
Almansour, I., Golovan, S., Pickens, J., Salley, K., & Roberts, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5664233/v1 · Cited by 2
Evaluating the integrity of polymersomes by FRET for optimization of the lyophilization parameters
Liu, Y., Hu, F., Wang, S., Xu, M., Yu, Q., & Wang, L. (2022) · Polymer · doi:10.1016/j.polymer.2022.125375 · Cited by 1
Role of nanotechnology in microbiome drug development
Vedarethinam, V., & Jeevanandam, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15435-5.00018-9 · Cited by 1
Formulation of recombinant Lactococcus lactis as an oral vaccine candidate for COVID-19
Fatwa, N. A., Medacyntia, D., Puspita, O. E., Adianingsih, O. R., Winarsih, S., Widodo, N., & Yurina, V. (2024) · Pharmacy Education · doi:10.46542/pe.2024.249.614 · Cited by 1
Lipid nanoparticles in medicine: advances in diagnostics, therapeutics, and future directions
Tran, V. A., Vo, T. T. T., Thanh, N. C., Tran, T. D., & Tran, T. N. A. (2025) · Nano Futures · doi:10.1088/2399-1984/ada900 · Cited by 1
Optimization of Bipolar Microsecond Electric Pulses for DNA Vaccine Delivery
Williamson, R. H., DeWitt, M. R., Elhanafi, D., Zaharoff, D. A., & Sano, M. B. (2025) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2025.3547311 · Cited by 1
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19
Kole, E. B., Jadhav, K., Singh, R., Verma, R. K., Chatterjee, A., & Naik, J. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053265 · Cited by 1
Scaria, P. V., Rowe, C. G., Košík, I., Hu, Z., Renn, J. P., Alani, N., Kemanli, P., Orr-Gonzalez, S., Lambert, L., Adeyemi, K., et al. (2025) · Vaccines · doi:10.3390/vaccines13060648 · Cited by 2
Immunogenicity of neoantigens: From CAR-T cell to various vaccines
Davodabadi, F., Arabpour, J., Goleij, P., Mohammadi, E., Taheri, M., Sethi, G., Dua, K., & Sarhadi, M. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125924 · Cited by 1
Cytoplasmic abundant heat-soluble proteins from tardigrades protect synthetic cells under stress
Xi, Y., Mao, J., Chen, S. J., Moghimianavval, H., Lee, Y. J., Panda, A., Huang, A. J., Zhou, D. H., Xu, L. A., Fu, K. Y., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72328-5 · Cited by 1
Implementation of FTA Elute Card for Viral RNA Storage and Cost‐Effective Wastewater Surveillance
Hui, Q., Pan, Y., Cullen, D., & Yang, Z. (2025) · Advanced Sensor Research · doi:10.1002/adsr.202500051 · Cited by 1
Saeed, T. S., Saeed, M. R., Abdullah, M. F., Qureshi, M. S., Saeed, A., Munawar, S., Saifullah, M., & Rana, I. (2025) · World Journal of Pharmacology · doi:10.5497/wjp.v14.i1.110200 · Cited by 1
Nathani, A., Padakanti, S. C., Bagde, A., & Singh, M. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107821 · Cited by 1
Arman, B. Y., Magri, A., Barbaglia, M. N., Petherbridge, L., Brook, J., Bharucha, T., Legge, I., Walsby-Tickle, J., Deats, M., Banerjee, S., et al. (2025) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2025.100467 · Cited by 1
mRNA based vaccines and therapeutics for parasitic infections: a comprehensive review
Hasan, M. W., Pan, J., Xia, N., & Chen, W. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03787-z · Cited by 1
Armored RNA technology as a clinical diagnostics tool for future pandemic preparedness
Tan, J. H., Mainali, P., Zhang, W., & Ow, D. S. (2026) · The Journal of Microbiology · doi:10.71150/jm.2510016 · Cited by 1
Advances in functional transcriptome analysis of Mycobacterium tuberculosis: a review
Sundaram, K., & Sridhar, R. (2026) · Molecular Genetics and Genomics · doi:10.1007/s00438-026-02374-7 · Cited by 1
Dyett, B., Alsaiari, S. K., Daristotle, J. L., Forster, T. A., Lau, A., Varshney, D., Afaneh, R., Hanna, A. R., Sloane, C., Mankus, D. V., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.75716 · Cited by 1
Chuai, X., Zhao, B., Wu, Y., Zhou, J., Ye, T., Yang, Y., Wang, C., Li, F., Zhang, K., Hu, J., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04557-1 · Cited by 1
Formulation of Peptide‐Based Nanoparticles Using a Microfluidic Device
Hammoum, T., Konate, K., Mousli, Y., Deshayes, S., Vivès, É., Nsamela, A., & Boisguérin, P. (2026) · Journal of Peptide Science · doi:10.1002/psc.70107 · Cited by 1
Metadata
- Authors
- Uddin, M. N., & Roni, M. A.
- Affiliations
- Mercer University (US)
- Peoria campus of the University of Illinois System (US)
- Corresponding author
- Roni, Monzurul A.
- Venue
- Vaccines
- Publisher
- MDPI AG
- Published
- 2021-09-17
- Volume
- 9
- Issue
- 9
- Pages
- 1033
- ISSN
- 2076-393X (ISSN-L)
- PMC
- PMC8473088
- OpenAlex
- W3200035370
- Cited by
- 371
- References
- 54
- Citations by year
- 2026: 50 · 2025: 92 · 2024: 81 · 2023: 80 · 2022: 65 · 2021: 1
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Vaccines (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Keywords
- mRNA vaccines, COVID-19 vaccines, SARS-CoV-2, vaccine stability, cold chain storage, storage temperature, vaccine delivery systems, mRNA degradation, resource-poor countries, mass vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
